Aditya Birla Sun Life Pharma & Healthcare Fund

An open ended equity scheme investing in Pharma and Healthcare Services Sector.
Data as on 30th September 2024
Fund Details
Investment Objective
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There is no assurance that the objective of the Scheme will be achieved.
Fund Category
Investment Style
Thematic (Equity)

Fund Manager
Mr. Dhaval Shah & Mr. Dhaval Joshi
Managing Fund Since
July 11, 2019 & November 21, 2022
Experience in Managing the Fund
5.2 Years & 1.9 Years
Load Structure (as % of NAV) (Incl. for SIP)
Entry Load Nil
Exit Load For redemption/switchout of units on or before 30 days from the date of allotment:1.00% of applicable NAV. For redemption/switch-out of units after 30 days from the date of allotment: Nil
Total Expense Ratio (TER)
Regular 2.28%
Direct 0.92%
Including additional expenses and goods and service tax on management fees.

AUM ₹
Monthly Average AUM 875.59 Crores
AUM as on last day 888.27 Crores
Date of Allotment
July 11, 2019
Benchmark
BSE Healthcare TRI
Other Parameters
Standard Deviation 16.02%
Sharpe Ratio 0.70
Beta 0.96
Portfolio Turnover 0.26
Treynor Ratio 0.12
Average P/E 38.58
Average P/BV 5.54
Average Dividend Yield 0.60
Note: Standard Deviation, Sharpe Ratio & Beta are calculated on Annualised basis using 3 years history of monthly returns. Risk Free Rate assumed to be 6.76% (FBIL Overnight MIBOR as on 30 Sep 2024) for calculating Sharpe Ratio

Application Amount for fresh subscription
₹ 1,000 (plus in multiplies of ₹ 1)
Min. Addl. Investment
₹ 1,000 (plus in multiplies of ₹ 1)
SIP
Daily/Weekly/Monthly: Minimum ₹ 100/-
NAV of Plans / Options ₹
Regular Plan Direct Plan
Growth 32.3600 35.1600
IDCW$: 22.7200 24.3100
$Income Distribution cum capital withdrawal
PORTFOLIO
Issuer
% to Net Assets
Pharmaceuticals & Biotechnology 71.98%
Sun Pharmaceutical Industries Limited 14.89%
Cipla Limited 7.82%
Torrent Pharmaceuticals Limited 7.44%
Aurobindo Pharma Limited 5.61%
Ajanta Pharmaceuticals Limited 4.66%
Lupin Limited 4.05%
Alkem Laboratories Limited 3.39%
ALEMBIC PHARMACEUTICALS LIMITED 3.26%
Abbott India Limited 2.62%
J.B. Chemicals & Pharmaceuticals Limited 2.60%
Dr. Reddys Laboratories Limited 2.42%
IPCA Laboratories Limited 2.33%
Strides Pharma Science Limited 2.12%
Gland Pharma Limited 1.97%
Zydus Lifesciences Limited 1.92%
Issuer
% to Net Assets
Emcure Pharmaceuticals Ltd 1.47%
Mankind Pharma Ltd 1.27%
Akums Drugs & Pharmaceuticals Ltd 1.25%
Sanofi India Limited 0.88%
Healthcare Services 15.51%
Apollo Hospitals Enterprise Limited 5.99%
Fortis Healthcare Limited 5.04%
Vijaya Diagnostic Centre Limited 2.39%
Jupiter Life Line Hospitals Ltd 2.09%
Insurance 3.61%
Medi Assist Healthcare Services Ltd 1.94%
Star Health & Allied Insurance Limited 1.67%
Chemicals & Petrochemicals 0.91%
Vinati Organics Limited 0.91%
Cash & Current Assets 7.99%
Total Net Assets 100.00%

Past performance may or may not be sustained in future. The above performance is of Regular Plan - Growth Option. Kindly note that different plans have different expense structure. Load and Taxes are not considered for computation of returns. When scheme/additional benchmark returns are not available, they have not been shown. Total Schemes Co-Managed by Fund Managers is 1. Total Schemes managed by Mr. Dhaval Shah is 8. Total Schemes managed by Mr. Dhaval Joshi is 39. Click here to know more on performance of schemes managed by Fund Managers.
Note: The exit load (if any) rate levied at the time of redemption/switch-out of units will be the rate prevailing at the time of allotment of the corresponding units. Customers may request for a separate Exit Load Applicability Report by calling our toll free numbers 1800-270-7000 or from any of our Investor Service Centers.

# Scheme Benchmark, ## Additional Benchmark
For SIP calculations above, the data assumes the investment of ₹ 10000/- on 1st day of every month or the subsequent working day. Load & Taxes are not considered for computation of returns. Performance for IDCW option would assume reinvestment of tax free IDCW declared at the then prevailing NAV. CAGR returns are computed after accounting for the cash flow by using XIRR method (investment internal rate of return).Where Benchmark returns are not available, they have not been shown.
Past performance may or may not be sustained in future. Returns greater than 1 year period are compounded annualized. IDCW are assumed to be reinvested and bonus is adjusted. Load is not taken into consideration.

This page is a part of the October 2024 Factsheet of Aditya Birla Sun Life Mutual Fund. Click on https://mutualfund.adityabirlacapital.com/empower/ for the digital factsheet.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.